Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Astute Medical said it’s in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
Last month, San Diego-based Astute won 510(k) clearance for NephroCheck, which is used to test for acute kidney injury, or AKI, in patients who have recently suffered a serious cardiac or respiratory event. Astute said its the first biomarker test for AKI to be approved by the FDA. Read more
It’s been 10 years since HealthEdge got its start and the healthcare software company is still standing. But that doesn’t mean it’s been standing still.
Burlington, Mass.-based HealthEdge last week closed on $30 million in new venture funding, according to a regulatory filing. So far, the company hasn’t said how it plans to spend its new wealth, although recent industry events will likely dictate some of those strategy decisions. Read more
InspireMD said today that it’s halting enrollment in a clinical trial of its flagship MGuard stent to focus on developing new drug-eluted stents with an unnamed strategic partner, abandoning plans to bring the MGuard device to the U.S. market.
The news sent NSPR shares down 5.0% to $1.90 apiece as of about 11:30 a.m. today. Read more